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1. Introduction 
1.1 Trends in R&D spending and production of new drugs 
Due to the excessive new product research opportunities and limited financial resources, 
deciding which new pharmaceutical products to develop can be a challenging and lengthy 
process for many pharmaceutical companies.  The returns on investment are attractive, but 
they vary considerably between drugs. New pharmaceutical products usually undergo 
costly and time-consuming testing before receiving government approvals for distribution 
to patients (Congressional Budget Office, 2006).  
Only about one percent of researched chemical molecules withstands the three phases of 
clinical trials, the scrutiny of the Food and Drug Agency (FDA), and becomes available for 
patient use. In addition, research and development (R&D) costs can reach more then $800 
million to develop and test a potential drug, so the selected product must return at least the 
accrued financial expenditures over its lifecycle (Nelson, 2009). With such high development 
costs and low probability of product success, project-prioritization and new product-
portfolio selection are of high importance to pharmaceutical managers.  Trading off 
available resources and investment opportunities helps identify drugs worthwhile to bring 
to market (Ogawa & Piller, 2006).  
In the pharmaceutical industry, the risk management problem includes deciding which new 
products to develop, continue to research, terminate, and invest in. These decisions include 
trading off risks, returns, and time horizons for future payoffs. In theory, such tradeoffs are 
easily undertaken by optimization problems; however, the complexity and uncertainty of 
the new drug development process can make the optimal solution hard to obtain, and may 
result in employing less complicated, and therefore, less precise methods of new product 
identification (Gino & Pisano, 2006).  
This chapter will focus on assessing the different risk management methods employed by 
pharmaceutical executives in the new product portfolio evaluation and consequently, which 
pharmaceutical products to bring to market. First, however, a review of the product 
development process, as well as the costs associated with research and development of new 
drugs in the U.S. will be presented. The process of product development will be described as 
it happens in the United States, although the R&D approach is not that different between the 
U.S. and the European countries. After the short R&D process summary, a description of the 
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risk assessment methods will follow. Pharmaceutical executives will find this chapter useful 
in making their product portfolio investment decision, as it will list several well known and 
widely used techniques of risk evaluation, as well as provide guidance on how they 
compare to each other, how they differ, and when should they be used.  
2.The cost of developing a new drug 
Over the past 20 years, the total costs associated with research and development (R&D) of 
new drugs has tripled. In 1980, U.S. pharmaceutical companies spent a total of $5.5 billion 
on research and development of pharmaceutical products, while in 2003, these costs 
increased to more than 17 billion (NSF, 2005). Continued growth in the R&D spending, 
however, has just a small effect on the pace at which new drugs have been developed in the 
past 20 years, as the number of innovative molecules in research has steadily increased 
(Congressional Budget Office, 2006).  
On average, it is estimated that R&D of new innovative pharmaceutical products costs 
nearly $802 million, and takes about 12 years for a pharmaceutical company to bring a drug 
to market (DiMasi et al., 2003). The R&D cost estimates include the actual accrued R&D 
expenditures that are estimated at $403 million, as well as expenditures of failed projects 
and the value of foregone alternative investments, which in total amount to $399 million 
(DiMasi et al., 2003; Rawlins, 2004). 
R&D costs for new drugs are highly variable, and depend on several factors that include the 
type of drug being developed, whether the drug is based on either a new molecular entity 
(NME) or it is an incremental modification of an existing product, the likelihood of product 
failures and government agency (i.e. Food and Drug Agency) approvals, and finally the 
expected revenues associated with product sales (Congressional Budget Office, 2006).  In the 
next few sections, these topics will be described, as well as their impact on driving the R&D 
costs and development decisions of new and innovative pharmaceutical products. 
2.1 Types of pharmaceutical products in development 
2.1.1 Acute illness vs. Chronic disease product research 
Until the late 1980s, pharmaceutical companies invested mostly in treating acute illnesses1, 
such as common colds, flu, and headaches, as these products are usually cheaper to develop, 
and can provide a quick return on investment (Congressional Budget Office, 2006). In the 
past 30 years, the industry’s developmental efforts have grown to include therapeutic 
classes, such as diabetes, cancer, and cardiovascular diseases. These diseases are referred to 
as chronic illness2, and tend to develop slowly over time. They can never be cured, and 
require advanced treatment (Congressional Budget Office, 2006).  
The shift in the product development type is associated with the changing population 
demographics. For example, today in the U.S., there are almost 100 million adults that are 50 
                                                 
1 An Acute Illness typically starts suddenly and is short lived. Two common examples are colds and the 
flu. Acute illnesses, caused by viruses, may go away by themselves, while others can be cured either 
with antibiotics or other medical treatment (Carlson, 2008).  
2 A Chronic Illness develops slowly over time and lasts a long time. Examples of common chronic 
illnesses include diabetes, arthritis, congestive heart failure, and Alzheimer's disease. Chronic 
conditions are typically caused by multiple factors including family history, diet, stress levels, and 
surrounding environment. Some chronic diseases will never be cured, and require advanced treatment 
(Carlson, 2008). 
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years old or older, and every year more than 3.5 million of Americans join this age group 
(Pirkl, 2009).  As a result of the changing demographics, the need for treating chronic 
conditions has been also increasing. It is estimated that a 1% growth, in the potential market 
for a category of drugs treating chronic disease, leads to an increase of roughly 4% in the entry 
of new drugs in that category (Lanjouw & Cockburn, 2001). In addition, growth in sales 
revenue for these types of drugs has provided the financial opportunities for additional 
research and development in this area, resulting in an increase in the number of targets in 
development from 500 to more than 3,000 in recent years (Congressional Budget Office, 2006). 
As the pharmaceutical products treating elderly population grows over time, the number of 
new drugs in therapeutic areas associated with treatment of young people, such as attention 
deficit hyperactivity disorder (ADHD), juvenile diabetes, pediatric vaccines, has declined in 
the recent years. The decrease is associated with the continuously declining number of 
births (in 2009, the U.S. birth rate was 14%), and consequently, lower expected returns on 
R&D investment related to products for treatment of children and teenagers (Center for 
Disease Control, 2010).  
2.1.2 New molecular entity vs. Incremental modification of an existing product 
The cost of R&D typically depends on the type of developmental drugs being pursued by 
pharmaceutical companies. There are two types of products developed in the 
pharmaceutical industry: new molecular entity and an incremental modification of an 
existing product. New molecular entity (NME) is defined as a drug that contains no active 
molecule previously approved by the FDA. In addition, an NME can also represent a ‘me-to-
drug’, which is still an innovative entity, but works in a similar way to an NME already 
available for patient use (Congressional Budget Office, 2006).   
The other drug category is an incremental modification of an existing product. The product 
modifications can include changes in drug delivery system, dosing scheme, as well as 
obtaining additional treatment and indication approvals (‘new label’). Most pharmaceutical 
companies pursue testing of current products to identify opportunities for patent extension 
for other product uses (Congressional Budget Office, 2006).   
On average, it is more costly to develop an NME compared to the incremental modification 
product, due to a longer time frame for development and testing, a higher probability for a 
clinical trial failure, and a more restrictive FDA approval system. On average, R&D costs of 
an NME are between $300 and $500 million higher compared to the product extension 
research costs (Piturro, 2006; Rawlins, 2004).  
2.2 The likelihood of product failures in clinical trials 
Research and development of a new pharmaceutical product relies heavily on clinical 
research and product testing. Product clinical trials are conducted to collect safety and 
efficacy data on the researched molecule. On average, only 1% of tested products 
successfully completes the three phases of testing, and can accrue more then $450 millions in 
R&D expenses (Rawlins, 2004). If a drug successfully passes through clinical trials, it usually 
is approved by the Food and Drug Agency (FDA) (or a European equivalent) for use in the 
general population (Pocock, 2004).  
Phase I clinical trials are the first stage of molecule testing in patients, and require from 20 to 
100 healthy volunteers. The test phase takes about 1 year to 2 years, and includes trials 
designed to assess safety and tolerability of a potential drug (Pocock, 2004). Once the initial 
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safety level of the studied drug has been confirmed in Phase I trials, Phase II clinical trials 
are performed on a larger group of about 20-300 patients to assess how well the drug works. 
They usually take anywhere from 2 to 4 years. Phase III clinical trials are performed on large 
patient groups, usually of 300–3,000 patients, depending upon the disease and medical 
condition studied. These experiments examine how effective the drug is in comparison with 
current treatments. Due to the size and comparatively long duration, even up to 6 years for 
chronic illness trials, Phase III trials are the most expensive, time-consuming, and difficult 
tests to design and successfully run (Pocock, 2004). 
2.3 Food and drug agency new drug approvals 
Once the new pharmaceutical product positively tests in clinical trials, the next step is to obtain 
an approval from a federal agency responsible for regulating pharmaceutical products 
available for patient use. In the U.S., this agency is called the Food and Drug Administration 
(FDA), while in the European Union it is called the European Medicines Agency (EMEA).  
In the U.S., the Food and Drug Administration (FDA) is the federal agency responsible for 
protecting and promoting public health through the regulation and supervision of food, 
pharmaceutical, and healthcare products.  The group responsible for the pharmaceutical 
product evaluation is the Center for Drug Evaluation and Research (CDER). The center 
evaluates new drugs before their availability for patient use, while ensuring that potential 
drug candidates work correctly, and their health benefits to patients outweigh their known 
risks. The review process can take up to two and a half years, and the obtained approvals 
allow the approved product to be sold only with a prescription (FDA, 2010).  
On average, one-third of new drugs applications submitted to the FDA are for new 
molecular entities (NMEs). Most of the rest are for incremental modification of existing 
drugs, which include the additional health conditions, for which an existing drug can be 
prescribed. In the past 15 years, the FDA approval rate declined, and the total number of 
NMEs approved each year fell from 53 in 1996 to 20 in 2005. The drop in approvals might be 
a result of longer research and development (R&D) cycles, and increased scrutiny of new 
pharmaceutical products by federal agencies (Congressional Budget Office, 2006).    
2.4 Sales, revenue, advertisement, and patent impact on development of new drugs 
The current and future R&D expenditures are also associated with the expected sales and 
revenue trends from launching new drugs to market. Usually, the potential product will not 
be investigated if it is expected not to recover accrued R&D costs. 
2.4.1 Sales and revenues of new drugs 
In the past 20 years, the U.S. profit growth has been about the same every year during that 
time period. The average yearly return on revenue is about 17%. The high and consistent 
growth places the pharmaceutical industry as the third most profitable of all industries in the 
U.S., and second best industry to invest in (Fortune 500, 2009). In the past decade, retail sales of 
prescription drugs has increased by 250% from $72 billion to $250 billion, while the average 
price of prescriptions has more than doubled from $30 to $68 (Census Bureau, 2008). 
The continued profit growth is partially related to the drug exclusivity rights, ranging from 
3 years to 20 years after product approval for patient use. Patent protection enables the 
pharmaceutical companies to recover the costs of research and development through high 
profit margins for their drugs. When the patent protection for the pharmaceutical product 
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expires, a generic drug is usually developed and sold by a competing company (Kaufman, 
2005). 
2.4.2 Managed care and formulary status impact on new drug success 
Besides product’s exclusivity rights, managed care system and formulary status of the 
pharmaceutical drugs also impact the future profitability levels of the pharmaceutical 
industry. Private insurance (i.e. Keystone and Aetna) or public health bodies (i.e. Medicare 
and Medicaid) can restrict the drug access to patients through the use of formularies and 
required out-of-pocket expenses (Shih & Sleath, 2004).  
Government agencies also impact the prices and availability of pharmaceutical products by 
passing laws and bills enabling a greater access to healthcare services and drugs.  For 
example, in 2010, the U.S. Congress passed a Health Care Bill, mandating all American 
citizens to purchase either a privately owned or government provided insurance plan to 
improve a public access to healthcare services and providers, as well as pharmaceutical 
products (Tumulty, 2010). 
2.4.3 Pharmaceutical brand advertising impact on new drug success 
The last factor, impacting sales, revenue, and profitability of pharmaceutical companies, is 
advertising of pharmaceutical products already available for patient use. In the U.S., 
pharmaceutical companies spend nearly $19 billion a year on pharmaceutical product 
promotion to impact sales numbers and profitability margins of their products (Moynihan, 
2003).  
Product advertising is common in healthcare journals, as well as through more mainstream 
media routes, such as radio and TV (Moynihan, 2003).  Pharmaceutical companies also 
promote directly to healthcare providers via employing sales representatives. Every year 
more then $5 billion is spent to support this type of promotion (Robinson, 2003). Finally, 
with the technological development of computers and handheld devises, such as Smart 
Phones and iPads, pharmaceutical brand advertising has also moved into the digital arena. 
Brand specific websites, as well as electronic detailing to physicians have become a popular 
venue of pharmaceutical promoting in the last 5 years (Howie & Kleczyk, 2011b).   
2.5 Summary of the new pharmaceutical product R&D process and associated costs  
New pharmaceutical products usually undergo costly and time-consuming testing before 
receiving government approvals for distribution to patients (Congressional Budget Office, 
2006). Only about one percent of researched chemical molecules can withstand the three 
phases of clinical tests, the scrutiny of the Food and Drug Agency (FDA), and becomes 
available for patient use. Research and development (R&D) costs have reached more then 
$800 million, and the product development process takes 12 years to complete. As a result, 
the selected pharmaceutical molecule must return at least the accrued financial expenditures 
over its lifecycle (Nelson, 2009).   
With the changes in demographic population, as well as enhancements in technology, more 
emphasis is placed on chronic illness product development, instead of acute illness product 
development. Although these drugs are more expensive and require more time to develop, 
they have the opportunity to return not only the invested financial capital, but also increase 
significantly net profits of the pharmaceutical companies, due to the changing population 
demographics towards a higher proportion of elderly citizens. With the continued high 
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spending allocated to advertising of pharmaceutical products, as well as increased use of 
internet and digital media to inform healthcare providers and patient population of their 
treatment options, expected sales and revenues can be increased even more. The only barrier 
in the entire process is the rate of FDA approvals and the formulary status of the new 
products, which tend to slow down the speed at which products are brought to market, as 
well as their affordability and access to the patient population.  
3. Risk management evaluation methods  
Deciding which new products to develop is a major challenge for many pharmaceutical 
companies with an excess of opportunities, but limited resources. Project prioritization and 
new product-portfolio selection has long been the domain of the new product arm of the 
corporation (Blau et al., 2000). Pharmaceutical product development, as any other 
management task, requires important decisions about the tradeoffs between the available 
resources, as managers decide which drugs to bring to market (Ogawa & Piller, 2006). 
Assuming a fixed research and development budget, the management problem includes 
deciding which new products to develop, continue to research, terminate, and invest in. In 
making these decisions, managers face tradeoffs between risks, returns, and time horizons 
for future payoffs. In theory, such tradeoffs are easily tackled by optimization problems; 
however, the complexity and uncertainty of the new drug development process can make 
the solution hard to obtain, and result in employment of less complicated, and therefore, 
less precise methods of new product identification (Gino & Pisano, 2006). 
Currently in the pharmaceutical industry, there is no one recommended method of risk 
assessment for evaluation of investment opportunities. There are, however, a variety of 
methods cited that can help mangers in making these decisions. Depending on the needed 
precision, complexity, and objectives of the analysis, the pharmaceutical managers can 
choose between different risk management methods to meet their study goals. Due to the 
importance of selecting the right approach of risk evaluation, and making the right decisions 
in selecting products for investment, several of the currently utilized methods will be 
reviewed and evaluated in this part of the chapter (Howie & Kleczyk, 2011a).   
There are two types of risk management methods: Net Present Value (NPV) methods and 
Consumer Theory based approaches. These NPV based methods include Net Present Value 
of Income analysis, Capacity Constrained NPV approach, and Stochastic Dominance. All of 
the above methods account for the financial impact of the chosen alternatives (Grabowski & 
Vernon, 1998; Blau et al., 2000; Smit & Trigeorgis, 2006). The Consumer Theory based 
approaches do not take into account the financial aspects of the new product development 
and analyze consumers’ preferences for different product alternatives instead. These models 
usually involve Conjoint Analysis / Discrete Choice models, determining the most 
preferred product attribute mix (Dakin et al., 2006).  
The above methods will be compared to each other on the basis of the inputted information 
(i.e. R&D expenditures, future drug prices, and probability of FDA approvals, etc.), 
complexity of the theoretical model (i.e. mathematical simulations, econometric and 
statistical analyses), as well as the precision and reliability of the theoretical frameworks, in 
selecting product portfolios with the highest return on investment.  
3.1 Net present value (NPV) based risk assessment methods 
There are several NPV (otherwise known as a payoff) based methods of the new product 
development identification process. These approaches include Net Present Value of Income 
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(NPV) analysis, Capacity Constrained NPV approach, and Stochastic Dominance analysis. 
All of these methods account for the financial impact of chosen alternatives, but differ by 
their complexity level, precision, and reliability of product selection (Grabowski & Vernon, 
2000; Blau et al., 2000; Smit & Trigeorgis, 2006).   
3.1.1 Net present value of income analysis 
Until the late 1980s, cash flows, expected returns, and net present value of income were the 
key variables in the decision-making process of the new drug development and investment. 
The relationship between investment and cash-flow statements provided pharmaceutical 
managers with a working framework for resource-allocation decisions (Grabowski & 
Vernon, 1998). This most widely used framework, called the Net Present Value (NPV) of 
Income, is described by cash inflows and outflows being discounted back to their present 
value (PV), and then being summed together. As a result, NPV of Income is the sum of all of 
following terms:  
 NPV = ∑Rt/(1+i)t, (1) 
where t is the time of the cash flow, i is the discount rate defined as the rate of return that 
could be earned on an investment in the financial markets with similar risk, and Rt is the net 
cash flow (the amount of cash inflow minus cash outflow) at time t (Khan, 1993). This 
analysis is performed for every potential product, and the drug with highest NPV of income 
is usually selected for pharmaceutical investment, and future market availability and sales. 
Although the NPV of Income framework provides a very simple and clean approach of 
investment profitability, as potential product investments can be ranked by their NPV 
amount, it is still the subject to change, and depends on a range of prices and operating costs 
associated with the investment and development of new pharmaceutical products. Demand, 
drug prices, as well as development and operating costs are the source of uncertainty within 
the framework. Modeling this uncertainty is the primary struggle observed within this 
approach (Grabowski & Vernon, 1998).  
3.1.2 Capacity constrained NPV approach 
In the early 1990s, pharmaceutical managers started leveraging a Capacity Constrained NPV 
approach to evaluate new potential pharmaceutical products. This method includes analysis 
of capacity planning and development management. This approach not only focuses on the 
cash flows and NPV framework, but also on the rate of FDA approvals and success rate of 
clinical trials. As a result, the new additions to the model account for the uncertainty 
associated with the dynamics of the pharmaceutical market (Rogers et al., 2004).   
In 2000, Blau et al. introduced a probabilistic simulation model of a pharmaceutical product 
development into this framework to prioritize candidate drugs, based on their risk-reward 
ratios. Their approach captures the complexity of the new pharmaceutical product research 
and development process, by incorporating probability of clinical trial success into the NPV 
concept (Blau et al., 2000; Lave et al., 2007).  As a result, this model helps select innovative 
product candidates that provide an acceptable exposure level to risk, while also providing 
adequate financial returns.  
The chosen risk level depends on the risk attitude of the management and stakeholders, as 
well as the status of the current commercial products and the characteristics of new drug 
candidates already in the development pipeline. A risk-averse management might prefer 
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molecules with high technical success ratio and low resource requirement, while a risk-
taking management might be willing to push molecules with greater returns at a greater risk 
(Blau et al., 2000). Most of the R&D drug information is generally available from researchers 
and engineers developing these products, while sales and marketing executives can provide 
estimates for expected sales upon marketplace launch (Blau et al., 2000).   
A simulation model, using data representing R&D related variables, as well as expected 
sales and revenues, is usually used to analyze the different investment options, while 
incorporating the risk-reward analysis and the probability distribution of production 
success. Once a portfolio of molecules is selected, the next issue is the speed at which these 
molecules can be pushed through the developmental and production pipeline, without 
violating the resource constraints, and therefore maximizing the net present value (NPV) of 
the selected portfolio. This is a ‘resource constrained scheduling problem under uncertainty’ 
and involves use of linear mathematical programming for the analysis (Blau et al., 2000). 
The problem is usually described as maximizing a NPV function subject to multiple 
constraints (financial and human capital resources): 
 Maximize a NPV function: F(x1; x2; … ; xn) (2) 
Subject to the following constraints:  
a1,1x1 + a1,2x2 + … +a1,nxn ≤ b1  
a2,1x1 + a2,2x2 + … +a2,nxn ≤ b2  
a3,1x1 + a3,2x3 + … +a3,nxn ≤ b3 
... 
 an,1x1 + an,2x2 + … +an,nxn ≤ bn, (3) 
where (x1 ….xn) define the inputs for the NPV optimization, and bn represents the constraint 
values. Constraints are usually defined as human and financial capital, time frame of 
product development, expected sales and revenues, and any other important to the 
management variables that should be controlled for when deciding, which potential 
molecules to invest in and bring to market (Champ et al., 2003). 
The constrained problems can range from a single project optimization with no resource 
constraints (Schmidt & Grossmann, 1996) to a more complicated problems defined by 
sequencing and scheduling of multiple testing tasks under resource constraints for a fixed 
set of products (Jain & Grossmann, 1999). To estimate the latter approach, a mixed-integer 
linear programming (MILP) model is usually utilized, and maximum resource availability is 
employed to enforce resource constraints (Honkomp, 1998). In 2003, Submarinian et al. even 
further extended the framework by formulating a simulation-optimization problem that 
combines mathematical programming with discrete choice simulation to also account for 
planning and scheduling uncertainty.  
Although these models account for the high level of complexity regarding new product 
development, they tend to be time-consuming, and are not easily executable by 
pharmaceutical managers. Consequently, not many pharmaceutical executives actively use 
this type of product portfolio optimization methodology, and tend to turn to easier and more 
practical ways of deciding, which products to develop and bring to market (Baker, 2002). 
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3.1.3 Stochastic dominance method 
As the Capacity Constrained NPV approach tends to be time-consuming, and rather difficult 
to implement by pharmaceutical management, Kleczyk (2008) applied a Stochastic Dominance 
methodology to eliminate the complexity in the decision of new chemical molecule 
investment. Stochastic Dominance evaluates the pharmaceutical product development process 
and chemical molecule prioritization via accounting for not only the uncertainty in drug 
prices, but also for development and operating costs related to product research and 
development (R&D). In addition, it is an intuitive and easily implemented tool that is uniquely 
suited to the objectives of new product development selection process (Kleczyk, 2008).  
Stochastic Dominance is usually employed in the analysis of financial portfolio 
optimization, which attempts to maximize financial portfolio’s expected return for a given 
amount of risk, or equivalently to minimize risk for a given level of expected return, by 
carefully choosing the appropriate investment choices (Edwin et. al, 1997). The basis for this 
method is not only how each potential product performs on their own (i.e. NPV), but also 
how each potential product changes its expected revenues relative to other products’ 
changes in their expected revenues too (Edwin et al, 1997). The analysis includes trading off 
risk and expected returns. For example, for a given amount of risk, the method describes 
how to select a potential product with the highest possible expected return; and for a given 
expected return, how to select a drug with the lowest possible risk (Markowitz, 1952).  
The framework makes many assumptions about pharmaceutical managers and drug 
companies, including the use of Normal Distribution function3 to model expected returns, the 
utility maximization framework4, unlimited credit availability to the pharmaceutical 
companies, and no transaction costs or federal and state taxes. Unfortunately, in reality, some 
of these assumptions, such as no transaction fees and unlimited credit amount available for 
lending, are relaxed to better represent the current environment, and provide realistic 
estimates of potential chemical molecules’ payoffs. As a result, more complex versions of the 
financial portfolio model can take into account a more sophisticated view of the world, such as 
one with non-normal distributions and taxes (Markowitz, 1959; Shleifer, 2000). 
There are two types of Stochastic Dominance methods that can be employed in the analysis 
of potential pharmaceutical products for market use: First and Second Degree Stochastic 
Dominance. The First Degree Stochastic Dominance (FSD) informs which potential 
product’s NPV distribution dominates all other choices. For example, if a decision maker 
prefers NPV distribution for molecule 1, which is mathematically presented as [f(xi)], to 
NPV distribution for molecule 2, which is mathematically presented as [g(xj)], then f(xi) 
dominates g(xj) by FSD:  
 f(xi)≥ g(xj) by FSD. (4) 
As a result, the cumulative probability distribution function5 of NPV for molecule 1, [F(xi)], 
is less or equal to cumulative probability distribution function of NPV for molecule 2, 
[G(xj)], (Kleczyk, 2008): 
                                                 
3 Normal Distribution Function describes real-valued random variables that tend to cluster around a 
single mean value (Varian, 1992). 
4 The Utility Maximization Framework represents maximization of a utility function based on a 
specified pharmaceutical company’s financial resource constraint requirement (Varian, 1992). 
5 Cumulative Probability Distribution Function represents the probability that a real-valued random 
variable X with a given probability distribution will be found at a value less than or equal to x (Varian, 
1992). 
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 F(xi) ≤ G(xj). (5) 
Furthermore, when molecule 1 dominates molecule 2, the expected value of the payoff for 
molecule 1, [NPVf(xi)],  will be greater than the expected value of the payoff for molecule 2, 
[NPV(g(xj)] (Kleczyk, 2008): 
 NPV(f(xi)) ≥ NPV(g(xj)). (6) 
The other commonly used type of Stochastic Dominance is the Second Degree Stochastic 
Dominance (SSD). For two chemical molecules 1 and 2, molecule 1 has second-order 
stochastic dominance over product 2, if the former is more predictable, involves less risk, 
and has at least as high of a mean. All risk-averse expected-utility maximizers prefer a 
second-order stochastically dominant potential product to a dominated product (Kleczyk, 
2008).  In terms of cumulative probability distribution functions: [F(xi)] of NPV and [G(xj)] of 
NPV, chemical molecule 1 is second-order stochastically dominant over molecule 2, if and 
only if, the area under [F(xj)] of NPV is less than or equal to that under [G(xj)] for all real 
numbers [R] x, with strict inequality at some x:  
 ∫-∞ x F(xi) ≤ ∫-∞ x G(xj), for x € R. (7) 
The analysis typically assumes that all managers are risk-averse, and therefore, no investor 
would choose a potential molecule that is second-order stochastically dominated by some 
other molecule (Kleczyk, 2008). 
The inputs needed to perform this type of analysis are similar to those used in the NPV of 
Income and Capacity Constrained approaches, and include the excepted sales, revenues, 
potential product sales price point, operating costs, taxes, as well as the probability of 
passing the clinical trial and being approved by the FDA. The risk level can be adjusted 
depending on the management risk aversion level and product portfolio in the company’s 
pipeline.  The above analyses are usually conducted using Monte Carlo simulation and 
sensitivity analysis to indentify, which potential products are worth of pharmaceutical 
companies to invest in. The final stage of the analysis involves comparing between NPV 
values for each molecule, and choosing a molecule with the highest NPV, as a 
recommendation for pharmaceutical company’s investment. The model can be extended to 
incorporate a linear programming approach, in order to add workforce and planning 
constraints into the model. The extension, however, implies that the analysis may again 
morph into a complex and time-consuming framework that might be difficult for 
pharmaceutical executives to execute on (Kleczyk, 2008).  
3.1.4 Summary of the NPV based risk assessment methods 
In summary, the basic NPV of Income analysis and Stochastic Dominance are simple 
methods to implement by pharmaceutical management, when prioritizing portfolio of 
chemical molecules. The NPV framework has been used for more than 80 years in the 
decision of resource allocation by estimating the net present value of the expected future 
revenues and expenses. Stochastic Dominance allows for executing against the financial and 
strategic company goals, while controlling for the important factors of the FDA approvals 
rate, the clinical trial success rate, expected sales and revenues, operating costs, and the tax 
base. Both of the above approaches allow for comparing NPVs of all potential products, and 
choosing the molecule with the highest expected NPV. 
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The items not accounted for in these two approaches are the production capacity constraints 
that include production scheduling, human capital availability, and currently produced and 
available for patient use drugs. The Capacity Constrained NPV approach accounts for these 
constraints by including them in the maximization of the NPV function. Both of the 
Stochastic Dominance and NPV methods can be extended to include the additional 
assumptions; however, the optimization process may become more complicated, time-
consuming, and therefore might be not easily understood by pharmaceutical executives.  
3.2 Consumer theory based risk assessment methods  
There are also other risk management methods that help in deciding, which new chemical 
molecules to invest in and bring to market. They do not necessarily take into account the 
financial aspects of new product development, but rather analyze healthcare providers’ 
preferences for different potential product alternatives. These models are usually based on 
the Consumer Theory, and involve employment of Conjoint Analysis (CA) (otherwise 
known as Discrete Choice Analysis) models, determining the most preferred new product 
attribute mix (Dakin et al., 2006).  
The Conjoint Analysis (CA) framework has been applied successfully to several marketing 
decisions, including designing of new products, targeting market selections, pricing of new 
products, and studying competitive reactions. One of the advantages of CA is its ability to 
answer various ‘what if’ questions when employed for analysis of hypothetical and /or real 
choice alternatives (Rao et al., 2008). This approach, however, can be very lengthy and 
complicated, due to the multiple steps required to design and complete the research. The 
required steps include, but are not limited to: a development of survey instruments, 
development of product stimuli based on a number of potential pharmaceutical product 
attributes in consideration, interviews of healthcare professionals and patients, an 
econometric and statistical analysis, mathematical simulations, and employment of the 
estimates in tackling any managerial problems, such as new product forecasting. 
The Conjoint Analysis (CA) is a stated-preference study that uses a survey instrument, as 
well as an experimental design to elicit pharmaceutical costumers’ preferences for 
pharmaceutical goods.  Pharmaceutical customers are usually represented by healthcare 
providers and patients. They participate in market research studies to provide their 
responses to survey questions, regarding alternatives of pharmaceutical products, varying 
in attribute levels to inform their preferences for multiple states of a potential drug.  The 
introduction of the expected drug price and / or formulary status of the potential product, 
as an attribute, extends the application of the method into welfare analysis. Based on the 
preference function knowledge, simulation and optimization algorithms aid the process of 
determining the preference level for each product-attribute combination (Champ et al., 2003; 
Rao, 2007).  
3.2.1 Theoretical framework: random utility maximization theory 
The theoretical model, guiding the CA preference elicitation methodology, is the Random 
Utility Maximization (RUM).  RUM is based on consumers’ (i.e. healthcare providers and 
patients) choices from a set of competing alternatives of potential pharmaceutical products.  
Each survey respondent chooses the most preferred alternative from a set of drug 
alternatives, while at the same time making tradeoffs between attributes of each alternative.  
Each respondent is trying to select an alternative that would provide them with the highest 
satisfaction, otherwise known as utility (Champ et al., 2003).   
www.intechopen.com
 
Risk Management Trends 
 
240 
The basic problem of utility or preference maximization represents the set of all 
pharmaceutical chemicals (alternatives) satisfying financial resource constraints. The 
financial constraint can include the financial restrictions of pharmaceutical companies, 
healthcare providers, and patients.  The company’s primary end-users’ (i.e. physicians, 
nurses, patients, etc.) are assumed to have preferences for each potential new product 
within a developmental product set X. As a result, the preference maximization problem is 
defined as maximization of a utility function based on a specified financial resource 
constraint requirement (Varian, 1992): 
 Maximize utility function: u(x) (8) 
 Subject to: px ≤ m, where x is in X, (9) 
where u(x) represents the utility function, and px ≤ m represents the financial resource 
constraint, with m being the fixed amount of money available to a company for product 
R&D, as well as healthcare providers’ and patients’ available funds for medical and 
healthcare needs (Champ et al., 2003). 
3.2.2 Survey development process  
In order to forecast a product potential, a survey instrument has to be developed first. 
Healthcare providers are usually invited to participate in questionnaires created to elicit 
their preferences and attitudes regarding a set of potential products. The survey format 
varies from a paper version to an internet based exposure. The collected data is then 
analyzed via employing econometric and statistical tools. A Conjoint Analysis depends on 
the design of stimuli, which describes potential pharmaceutical product profiles.  
Employment of experimental design allows generating a set of potential drug profiles for 
review when surveying respondents (Champ et al., 2003; Rao, 2007).   
The survey information collected from healthcare providers include preference rating data of 
selected product alternatives, ranking of product profiles, and choosing the preferred product 
over another option. In case of preference rating surveys, ratings are collected from 
respondents using attribute based pharmaceutical product profiles. The rating scale questions 
appeal to many researchers, due to the simplicity of the econometric analysis, and the ease 
with which respondents answer rating questions. The rating scales values can rage from 1 thru 
5 values, where 1 is the least preferred, and 5 is the most preferred, to 1 thru 9 values, implying 
the same preference scheme, but a larger response variability (Champ et al., 2003). 
In the choice-based surveys, respondents rank a set of product profiles from most to least 
preferred. For example, a preferred hypertension product is selected from among multiple 
alternatives, described by set of product attributes, such as product efficacy and safety 
(Champ et al., 2003).  The framework assumes the most preferred profile to be chosen first 
from the choice set, followed by the second ranked alternative chosen from the remaining 
choice set, and so forth.  The participants might get fatigued, while proceeding through the 
sequence of choices, which in turn might result in unreliable analysis, and imprecise 
potential product forecast (Champ et al., 2003). 
In addition to selecting their preferred pharmaceutical product, healthcare providers are 
asked to present their anticipated use of the chosen alternatives when it becomes available 
on the market, as well as indentify the change in the use of the current treatment options, as 
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a result of the new entrant. Based on their responses, market share forecast for new products 
are developed to help in the decision-making process. The forecasts might vary from one 
single data point to monthly 1 to 5 year forecasts, depending on the need and confidence in 
the product potential predication (Howie & Kleczyk, 2011a). 
3.2.3 Econometric and statistical analysis 
The most commonly used econometric and statistical models, employed in estimation of 
healthcare providers’ preferences and attitudes for new products, include logit and probit 
models. Depending on the type of data collected, either binary or multinomial logit and 
probit models are employed. Binary choice models relate to either selecting or not selecting 
a presented product alternative; while multinomial models relate to choosing a product 
alternative from a provided set (ranking or rating exercise).  Multinomial probit and logit 
models are more often selected for the analysis of choosing the right product attribute 
combination, as pharmaceutical managers are mostly faced with evaluation of multiple 
chemical molecule alternatives at one time. 
Both probit and logit models are based on the utility maximization framework of a 
healthcare provider choosing a particular pharmaceutical alternative over another. As a 
result, the respondent also maximizes the probability of a potential product being chosen 
from a presented set of alternatives. The probability specification is expressed as a function 
of observed variables, relating to the pharmaceutical product alternatives and the 
respondent. In its general form, the probability [Pni] that a person n chooses a molecule 
alternative i is expressed as follows: 
 Pni = P(xni, xnj; sn, β ) for j ≠ i, (10) 
where xni is a vector of attributes of molecule i faced by a healthcare provider n, xnj is a 
vector of attributes of the other alternatives (other than i) faced by person n, sn is a vector of 
characteristics of person n, and β is a set of parameters that relate variables to probabilities, 
which are estimated statistically. A vector of respondent characteristics includes the type of 
treatment expertise, age, gender, geographic area of practice, and healthcare provider’s 
function at the medical office (i.e. nurse, physician, etc).  
Today’s econometric and statistical software include both of the above models in their 
analysis menu, so the preferred pharmaceutical molecule evaluation is easily executable. 
The econometric model estimates the coefficients for each product attributes [β], which then 
allow identifying the preferred product alternative with the greatest market potential. 
Mathematical optimizations and simulations are usually employed to compute forecasts for 
the different product alternatives and attribute combinations (Champ et al., 2003). 
3.2.4 Product potential analysis and forecasting 
The described econometric and statistical models allow indentifying the preferred chemical 
molecule for research and development. In addition, the results are used to simulate and 
compute market potential of each alternative, in terms of product market share, as well as 
expected sales and revenues. The market potential forecast can span from just one data 
point at the end of a defined time period to monthly predictions, spanning from 1 year to 
even to up to 5 years after product availability for patient use. These data points are 
analyzed by pharmaceutical mangers to inform their investment decisions into new 
chemical molecules. Alternatives with the greatest market potential are usually considered 
for the R&D investment (Champ et al., 2003; Howie & Kleczyk, 2011a).  
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While surveying healthcare providers, to learn their preferred treatment options, is the 
appropriate approach to learning the new product potential, the problem with this approach 
is respondents’ ability to correctly identify the ‘future drug use,’ once approved for patient 
use. These product ‘future use’ estimates can be unreliable and overstate the future 
prescribing behavior of the pharmaceutical drugs.  As a result, the overstatement leads to an 
unreliable forecast for the product potential (Howie & Kleczyk, 2011a).   
While experience may provide some guidance, as to how to correct for this overstatement, 
every product is unique, and the appropriate ‘correction factor’ is itself highly unreliable. 
Depending on the brand and treatment categories, the estimated product market shares are 
adjusted without employing a methodologically sound approach. For example, some 
pharmaceutical managers employ a rule of lowering these estimates by half and then by third 
to adjust for physician drug future prescribing overestimation (Howie & Kleczyk, 2011a).   
In 2011, Howie and Kleczyk analyzed healthcare provider level data for 75 product uptakes 
after their market availability combined with respondents’ pre-launch stated product uptake 
series. Based on their analysis, they developed a unique ‘correction factor’ for each service 
provider and each drug profile. Consequently, they determined the various levels of each 
drug’s expected performance.  The ‘correction factor’ is derived based on individual 
respondents’ answers to questions of product use and thoughts about the product profile. In 
addition, questions regarding the speed of new product adoption, perceptions of the 
product over the current product treatments, level of knowledge about the new product, 
and intended use (in either first or second line of therapy) are also employed to adjust each 
provider’s estimates. Their new approach of product potential estimation has been shown to 
be highly predictive of the actual future prescribing behavior of each healthcare provider.  
Their unique approach increases the forecast accuracy from R-square6 of 0.233 to 0.796 
(Howie & Kleczyk, 2011a), which can further help inform decision-making process when 
evaluating several chemical molecules for investment.  
3.2.5 Summary of the consumer theory based risk assessment methods 
As presented above, the Consumer Theory based framework is yet another way of 
managing risk when deciding which new product to develop. This approach can be based 
on healthcare providers’ preferences (as well as patients, pharmacists, and other healthcare 
decision makers, depending on the study objective) and their perceived needs for new 
patient treatment options. Based on their potential product preferences and predicted 
‘future use’ upon product availability, pharmaceutical managers are able to make informed 
investment choices of new chemical molecules. The output allows for analysis of future sales 
and revenues, and also for analyzing whether the proposed product meets the current 
market needs (product attribute evaluation). In addition, the improvements to the product 
market potential forecast, introduced by Howie and Kleczyk (2011a), allow pharmaceutical 
mangers to make even more informed decisions, regarding future product investment, due 
to increased reliability and precision of the data analysis.  
The above approach can also be inputted, as expected product sales / revenues, into the 
NPV based approaches. The combined analysis effort increases managements’ confidence in 
the potential product forecast results, as well as ensures that all aspects, related to product 
development, such as R&D costs, as well as clinical trials success and FDA approvals rates, 
                                                 
6 R-square refers to the fraction of variance explained by a model (Champ et al., 2003). 
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are accounted for in the process of choosing the new chemical molecule. Consequently, the 
management ensures that investment in the selected product profile will return 
pharmaceutical company the financial capital expenses accrued during the drug research 
and development process. 
3.3 Comparison of risk management methods 
As discussed in the above sections, there are several risk management methods that differ 
from each other with regards to inputs, complexity, and the precision of product potential 
evaluation. As there is no one recommended approach for risk assessment in the 
pharmaceutical industry, it is important to understand how these methods differ and which 
situations should be used in. This section compares the NPV and Consumer Theory 
approaches based on the following criteria: 1) theoretical model; 2) inputs (i.e. R&D 
expenditures, future drug prices, and probability of FDA approvals, etc.); 3) analysis (i.e. 
mathematical simulations, econometric and statistical analyses); 4) complexity of the 
framework; 5) the recommended use in the product selection process. The presented 
analysis can assist pharmaceutical managers in deciding on the appropriate risk 
management method for their product assessment process. 
As shown in Table 1 below, the Net Present Value of Income analysis is the simplest method 
of risk assessment in the pharmaceutical industry. It is based on the investigation of cash 
flows, requires fewest inputs, and is simple to compute, as well as to employ into the 
decision-making process. For example, this approach can be used for preliminary evaluation 
of the pharmaceutical products in development to indentify the potential candidates for 
investment, while requiring only limited information on future costs and revenues. In 
comparison to other methods, however, the NPV of Income analysis is the least reliable and 
precise in predicting the market potential of an evaluated product, and therefore 
recommending products for R&D (Grabowski & Vernon, 1998). 
When more precise forecast is required, but a moderately complicated approach is 
preferred, Stochastic Dominance is usually employed. As shown in Table 1, this framework 
is still somewhat simple, but provides more reliable investment recommendations. The 
required inputs include cash flows and rate of return, as well as the FDA approvals rate, 
clinical trial success rate, and financial resource information (i.e. tax rate, operating costs, 
etc). These additional variables improve the precision of the analysis, and help better guide 
the decision-making process (Kleczyk, 2008). 
When precision and reliability of the forecast are an issue, as well as capacity constraints (i.e. 
financial, workload, resource planning) are an important input into the analysis, the 
Capacity Constrained NPV approach is recommended.  This method provides highly 
reliable and precise product return on investment prediction, due to accounting for the 
many variables important in the development, production, and sales of pharmaceutical 
products. As mentioned previously, however, the main problem, with the Capacity 
Constrained NPV, is the complexity level of the analysis, as it requires a high level of linear 
mathematical programming knowledge, as well as utilization of mathematical optimization 
and simulation. The method is recommended for use after the initial assessment of the 
potential products for investment is completed, in order to aid resource allocation and 
management during the product research and development process (Blau et al., 2000).  
The last approach described in Table 1, the Conjoint Analysis method, can be also somewhat 
complex and time-consuming to employ, due to the multiple steps required to execute this 
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framework successfully (i.e. survey development, healthcare providers study recruitment, 
analysis, etc). Differently from the former methods, the Conjoint Analysis (CA) is based on 
the Consumer Theory instead of NPV, and analyzes end-users preferences for potential 
products. It is usually utilized by marketing mangers to help in forecasting product market 
potential (i.e. market share, revenue, sales), deciding order of product release to the market, 
as well as in the development of marketing strategies (i.e. market positioning, defining / 
confirming clinical end-point, etc). As it can be a reliable and precise forecasting tool, it is 
also employed as an input into the NPV based approaches to even further improve these 
methods’ precision and reliability. Differently from the NPV based methods, the required 
inputs include product profile information and development of a survey instrument. To 
account for the financial aspect of the analysis, the expected drug prices and the formulary 
status of the product might be included. The mathematical analysis can become somewhat 
complex, and usually involves use of econometric and statistical tools, such as regression 
analysis, as well as mathematical optimization and simulation, to help identify the best 
product / product profile / attribute mix that will also result in the highest expected return 
on investment (Champ et al., 2003).  
As the different methods of risk management vary with regards to the inputs, analysis, 
complexity of the framework, and the recommended use in the product selection process, 
pharmaceutical managers should consider the following criteria, when choosing the right 
approach for evaluation of potential pharmaceutical products: 1) the stage of the product 
development; 2) the preferred precision of the output; 3) the complicity of the model; and 
finally 4) the objective of the study. If quick and simple study of product assessment is 
needed, either the NPV of Income or Stochastic Dominance analysis should be an adequate 
tool to complete the task. If human and financial capital constraints are considered in the 
investment evaluation, then the Capacity Constrained NPV would be the preferred model. 
Finally, when product market share forecast still needs to be defined and / or preferred 
product attributes of a potential investment confirmed, the Consumer Theory based 
approach might be the best choice to pursue.  
4. Concluding remarks 
In this chapter, the research and development (R&D) process of new drugs, as well as 
methods of evaluating potential risks related to this procedure were discussed. As 
presented, new pharmaceutical products usually undergo costly and time-consuming 
testing, before receiving government approvals for distribution to patients.  At the end, only 
about one percent of researched chemical molecules withstands the clinical trials, the 
scrutiny of the Food and Drug Agency (FDA), and becomes available for patient use. The 
costs associated with the R&D process has reached more then $800 million in recent years, 
and they are continually increasing. The average time length of product development is now 
12 years, and will increase to even a longer time frame, due to the shift from the acute illness 
product development to chronic illness product development (Nelson, 2009). The shift is 
associated with a greater percent of elderly population, which is more prone to develop 
chronic diseases. Development of drugs that help either slow down or cure these types of 
diseases requires a longer time frame of clinical trials, as well as greater amounts of financial 
investments. Although these pharmaceutical products are more expensive and require more 
time to research and develop, they may return not only the invested financial capital, but 
also increase significantly net profits of pharmaceutical companies.  
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Net Present 
Value of Income 
Capacity 
Constrained NPV  
Stochastic 
Dominance 
Conjoint 
Analysis 
Theoretical 
Framework 
Net Present 
Value 
Net Present Value Net Present Value
Consumer 
Theory 
Inputs 
Expected R&D 
expenses; 
expected 
revenues; rate of 
return 
Expected R&D 
expenses; expected 
revenues; rate of 
return; company 
financial 
information (i.e. 
taxes base; 
operating costs; 
financial resource 
constraints); FDA 
approval rate; 
clinical trial success 
rate; workload & 
planning 
constraints; 
currently 
manufactured 
product portfolio 
Expected R&D 
expenses; 
expected 
revenues; rate of 
return; company 
financial 
information (i.e. 
taxes base; 
operating costs; 
financial resource 
constraints); FDA 
approval rate; 
clinical trial 
success rate; 
Product 
attributes & 
clinical end-
points; expected 
price point & 
expected 
formulary status 
*Survey 
instrument 
development 
Analysis 
Simple 
mathematical 
computation 
Linear 
mathematical 
programming; 
mathematical 
optimization & 
simulation 
Mathematical 
optimization & 
simulation; 
sensitivity 
analysis 
Regression 
analysis (probit 
/ logit); 
mathematical 
simulation & 
optimization 
Complexity Low High Moderate 
Moderately 
High 
Precision / 
Reliability   
Low level of 
precision & 
reliability 
High level of 
precision & 
reliability  
Moderate level of 
precision & 
reliability 
High level of 
precision & 
reliability 
Recommended 
Use 
Quick / 
preliminary 
product 
investment 
selection 
Selection of highest 
potential product 
that meets all pre-
specified criteria 
and constraints 
Selection of 
highest potential 
product with 
financial, clinical 
trials, and FDA 
approvals 
constraints 
Forecast of 
product sales / 
market potential; 
development of 
marketing / 
product 
positioning 
strategies; an 
input into the 
NPV based 
approaches 
(expected sales) 
Table 1. Comparison of Risk Management Methods 
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The promotional efforts of pharmaceutical products also impact the risk management and 
future investment returns of the new drugs. With the continued high spending allocated to 
the advertising of these products (Direct-to-Consumer advertising and personal promotion 
to healthcare providers), as well as increased use of internet and digital media to inform 
healthcare providers and patient population of their treatment options, the expected sales 
and revenues can be increased even more in the near future. The increased financial 
revenues provide return on the past R&D investments, but also develop a stream of 
financial capital for future developmental projects.  
The only, but quite a large, barrier in the entire product research and development process 
is the rate of FDA approvals and the managed care and / or formulary status of the new 
products. These agencies tend to slow down the speed at which products are brought to the 
market, as well as impact their affordability and access to the patient population. The FDA 
standards for product approvals are increasingly more stringent, while new drugs receive 
the lowest formulary status (a highest copay amount to be paid by patients) when launched 
to market for patient use, in comparison to more mature brands and generic competitors. To 
overcome the access and affordability issues, many pharmaceutical companies are assisting 
patients with their out-of-pocket costs to lower the financial burden, and to increase their 
product use.  However, with an expected increase in the number of generic products on the 
market, even if this strategy might not benefit pharmaceutical companies in the long run 
(Alazraki, 2011). 
In order to ensure recovering the high R&D costs invested by pharmaceutical companies, 
choosing the appropriate products for research and development requires important 
decisions about the tradeoffs between the available resources, as well as risk levels, returns, 
and time horizons for future payoffs. In theory, such tradeoffs are easily tackled by 
optimization problems; however, as discussed in this chapter, the complexity and 
uncertainty of the new drug development processes can make the solution hard to obtain, 
and might require employment of less complicated, and therefore, less precise methods of 
new product identification (Gino & Pisano, 2006). 
Most risk management methods employed in the pharmaceutical industry include two 
types of methods: NPV and Consumer Theory based, to solve the new product research and 
development problem.  As these method types differ on the basis of the analysis, inputs, 
precision and reliability of the approaches, as well as recommendations, knowing and 
understanding the differences between the various theoretical frameworks can help in 
selecting the right evaluation process of product selection and investment.  
However, it is also important to know that each approach investigates a different angle of 
the risk management problem, and multiple analyses are usually recommended to ensure 
making informed investment decisions. Starting with a quick and simple NPV of Income 
analysis of potential product, and extending it to Stochastic Dominance, followed by the 
Capacity Constrained NPV approach for increased forecast precision, should help in 
predicting the success probability of brining the product to market, and the required 
resources for development and production. The Consumer Theory based methods can help 
further define the best product attributes, product positioning, and estimate the true 
product uptake when available for patient use. Knowing possible challenges, as well as 
benefits of the product of choice can help managers to avoid potential product failures, and 
recommend a product or set of products that will maximize investment returns for the 
pharmaceutical company in the future. In addition, it is recommended not to limit the risk 
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management analysis only to performing the computation internally, but rather to inquire 
for a third party / expert opinion. Having an outside expert, provide an unbiased opinion 
on the product investment options, can only strengthen the decision-making process, and 
help guide successful investment choice for the company.  
In conclusion, the process of new pharmaceutical product research and development is 
complicated and requires a large financial and time investment. Since the financial and time 
costs are extensive, having the right tools in making investment decisions is vital in ensuring 
successful product selection. Currently available methods of risk management can help 
define the potential investment opportunities, and guide the selection process. These 
methods will grow to be even more important, as the R&D resources become in even more 
scares, and the product development costs increase. 
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